Acacia Pharma

Acacia Pharma is a hospital pharmaceutical company focused on the development and commercialisation of new nausea & vomiting treatments for surgical and cancer patients.

Acacia's lead project, BARHEMSYS™ for post-operative nausea & vomiting (PONV), has generated positive results in four Phase 3 clinical studies and expects to receive US market approval in 2019.

Its sister project, APD403 for chemotherapy induced nausea & vomiting (CINV), has successfully completed one proof-of-concept and one Phase 2 dose-ranging study in patients receiving highly emetogenic chemotherapy.

Acacia Pharma is based in Cambridge, UK and its US operations are centred in Indianapolis, IN. Acacia is listed on the Euronext Brussels exchange under the under ticker symbol ACPH.

Gilde Healthcare acted as founding investor and supported Acacia as lead investor in all subsequent investment rounds including at IPO.


Cambridge, United Kingdom